The Journal of Allergy and Clinical Immunology
Volume 114, Issue 5 , Pages 1183-1188 , November 2004

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

  • Roland Kaufmann, MD

      Affiliations

    • From Johann Wolfgang Goethe-Universität, Hautklinik, Frankfurt am Main
    • Corresponding Author InformationReprint requests: Roland Kaufmann, MD, Johann Wolfgang Goethe University Hospital, Department of Dermatology and Venereology, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.
    • ,
  • Regina Fölster-Holst, MD

      Affiliations

    • Christian-Albrechts-Universität, Hautklinik, Kiel
    • ,
  • Peter Höger, MD

      Affiliations

    • University of Hamburg, Department of Dermatology, Division of Paediatric Dermatology, Hamburg
    • ,
  • Diamant Thaçi, MD

      Affiliations

    • From Johann Wolfgang Goethe-Universität, Hautklinik, Frankfurt am Main
    • ,
  • Helena Löffler, MD

      Affiliations

    • Novartis Pharma GmbH, Clinical Research, Nürnberg
    • ,
  • Doris Staab, MD

      Affiliations

    • Charite-Virchow Klinikum, Kinderklinik und Poliklinik, Berlin
    • ,
  • Matthias Bräutigam, PhD

      Affiliations

    • Novartis Pharma GmbH, Clinical Research, Nürnberg
    • ,
  • for the CASM981CDE04-Study Group

Received 11 May 2004 ,Revised 6 August 2004 ,Accepted 6 August 2004.

  • Image Result

    Improvement in clinical symptoms of atopic eczema as assessed by EASI score during the double-blind and open-label phases.

    Improvement in clinical symptoms of atopic eczema as assessed by EASI score during the double-blind and open-label phases.

  • Image Result

    Improvement in clinical symptoms of atopic eczema in patients treated with pimecrolimus cream 1% during the double-blind phase. Mean total EASI score in patients with mild or moderate disease (IGA=2-3

    Improvement in clinical symptoms of atopic eczema in patients treated with pimecrolimus cream 1% during the double-blind phase. Mean total EASI score in patients with mild or moderate disease (IGA=2-3; A) compared with that seen in patients with severe or very severe disease (IGA=4-5; B).

  • Image Result
    Percentage of patients with an improvement of at least 50% from baseline according to the primary caregiver's assessment (visual analog scale). A, Pruritus. B, Sleep loss.

    Percentage of patients with an improvement of at least 50% from baseline according to the primary caregiver's assessment (visual analog scale). A, Pruritus. B, Sleep loss.

 Supported by Novartis Pharma GmbH.Conflict of interest statement: The following have a financial interest-relationship as follows. R. Kaufmann: grant-research support from Amgen, Aventis, Basilea, Biofrontera, Biogen, Centocor, Fumapharm, Fujisawa, Galderma, Genmab, Henkel, Hermal, Infectopharm, Leo, Medigene, Medimmune, Novartis, Schering, Schering-Plough, Serono, Smith & Nephew, and Versicor. D. Thaçi: grant-research support from Amgen, Aventis, Basilea, Biofrontera, Biogen, Centocor, Fumapharm, Fujisawa, Galderma, Genmab, Henkel, Hermal, Infectopharm, Leo, Medigene, Medimmune, Novartis, Schering, Schering-Plough, Serono, Smith & Nephew, Versicor; lecture honoraria from Novartis, Biogen, Fumedica, Hermal, Leo; consultant for Novartis and Fujisawa. R. Fölster-Holst: grant-research support from Novartis, Fujisawa, Hartmann and Stallergen; lecture honoraria from Novartis and Fujisawa; consultant for Novartis. P. Höger: grant-research support from Novartis; consultant for Novartis. D. Staab: grant-research support from Novartis and Fujisawa; lecture honoraria from Novartis. H. Löffler and M. Bräutigam are employees of Novartis Pharma GmbH.

PII: S0091-6749(04)02220-1

doi: 10.1016/j.jaci.2004.08.015

The Journal of Allergy and Clinical Immunology
Volume 114, Issue 5 , Pages 1183-1188 , November 2004

Article Tools

* Image Usage & Resolution